We develop a nanotechnology-based diagnostic kit for the early detection of neurodegenerative diseases, such as Alzheimer’s Disease Diagnostic kit for early detection of AD, as a screening test applicable for patients 45-55 yrs, focused on identifying key biomarkers of AD through labeling with a proprietary use of nanomaterial. CrystalNeuro is developing a biomarker test kit to be used at annual physical exam that will allow early detection of changes in human brain and cerebrospinal liquid leading to development of Alzheimer’s disease and other types of dementia. Our test kit is based on the use of nanomaterial with special properties. It will allow biomarker detection about 20 years prior statistically established age of symptoms appearance. After the biomarker is detected, nanotechnology will be used to minimize its effects on a body on molecular level. The same nanomaterial will be used for the development of targeted delivery of treatment to specific region. CrystalNeuro is considering two modes of biomarker detection – endomicroscopy and photoacoustic.
